MMX mesalamine for maintaining remission of ulcerative colitis (UC): Interim safety results

被引：0
|
作者：
Lichtenstein, Gary R.
Butler, Todd
Barrett, Karen
Stephenson, David
Joseph, Raymond E.
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Shire Pharmaceut Inc, Wayne, PA USA
[3] Shire Pharmaceut Inc, Basingstoke, Hants, England
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2006年 / 101卷 / 09期
关键词：
D O I：
10.14309/00000434-200609001-01106
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1106
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [1] Budesonide MMX and Mesalamine to Induce Remission in Patients With Ulcerative Colitis Reply
    Sandborn, William J.
    Travis, Simon
    Ballard, David
    GASTROENTEROLOGY, 2013, 144 (03) : E23 - E24
  • [2] MMX™ mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis
    Sandborn, W.
    Kamm, M.
    Lichtenstein, G.
    Barrett, K.
    Joseph, R.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S24 - S24
  • [3] Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis
    D'Haens, Geert
    Sandborn, William J.
    Barrett, Karen
    Hodgson, Ian
    Streck, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07): : 1064 - 1077
  • [4] Private practice experience switching chronic stable ulcerative colitis (UC) patients to mesalamine MMX
    Hilal, J.
    Shafran, I
    Burgunder, P.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S15 - S15
  • [5] MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
    D'Amico, Ferdinando
    Lusetti, Francesca
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (09) : 1425 - 1432
  • [6] Evaluation of the Pharmacokinetics and Safety of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis
    Cuffari, Carmelo
    Pierce, David M.
    Korczowski, Bartosz
    Fyderek, Krzysztof
    Van Heusen, Heather
    Inglis, Susi
    Palmen, Mary
    Hossack, Stuart
    Martin, Patrick
    GASTROENTEROLOGY, 2014, 146 (05) : S781 - S781
  • [7] The Effect of Ulcerative Colitis (UC) Remission Status Aft er Induction With MMX® Mesalamine on Long-Term Maintenance Therapy Outcomes (MOMENTUM Study): Induction Phase Results
    Rubin, David
    D'Haens, Geert
    Inglis, Susi
    Magee, Elizabeth
    Solomon, Dory
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S676 - S676
  • [8] Efficacy of MMX-mesalamine monotherapy for maintenance of remission in ulcerative colitis patients after mucosal healing
    Lopez-Diaz, J.
    Ferreiro, R.
    De la Iglesia, D.
    Lorenzo, A.
    Dominguez-Munoz, J. E.
    Barreiro-de Acosta, M.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S336 - S337
  • [9] MMX™ mesalamine is effective for the maintenance of ulcerative colitis remission in both left-sided and extensive disease
    Lichtenstein, Gaiy R.
    Kamm, Michael A.
    Karlstadt, Robyn
    Diebold, Ron
    Barrett, Karen
    Joseph, Raymond E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S462 - S462
  • [10] Once-Daily MMX Mesalamine in the Management of Ulcerative Colitis
    Blonski, Wojciech
    Buchner, Anna M.
    Lichtenstein, Gary R.
    CLINICAL MEDICINE INSIGHTS-GASTROENTEROLOGY, 2011, 4 : 7 - 13
12345